Bolander Johanna, Ji Wei, Leijten Jeroen, Teixeira Liliana Moreira, Bloemen Veerle, Lambrechts Dennis, Chaklader Malay, Luyten Frank P
Tissue Engineering Laboratory, Skeletal Biology and Engineering Research Center, KU Leuven, O&N 1, Herestraat 49, Box 813 13, 3000 Leuven, Belgium; Prometheus, Division of Skeletal Tissue Engineering, KU Leuven, O&N 1, Herestraat 49, Box 813 13, 3000 Leuven, Belgium.
Tissue Engineering Laboratory, Skeletal Biology and Engineering Research Center, KU Leuven, O&N 1, Herestraat 49, Box 813 13, 3000 Leuven, Belgium; Prometheus, Division of Skeletal Tissue Engineering, KU Leuven, O&N 1, Herestraat 49, Box 813 13, 3000 Leuven, Belgium; Department of Developmental BioEngineering, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Drienerlolaan 5, 7522NB Enschede, the Netherlands.
Stem Cell Reports. 2017 Mar 14;8(3):758-772. doi: 10.1016/j.stemcr.2017.01.005. Epub 2017 Feb 9.
Clinical translation of cell-based strategies for regenerative medicine demands predictable in vivo performance where the use of sera during in vitro preparation inherently limits the efficacy and reproducibility. Here, we present a bioinspired approach by serum-free pre-conditioning of human periosteum-derived cells, followed by their assembly into microaggregates simultaneously primed with bone morphogenetic protein 2 (BMP-2). Pre-conditioning resulted in a more potent progenitor cell population, while aggregation induced osteochondrogenic differentiation, further enhanced by BMP-2 stimulation. Ectopic implantation displayed a cascade of events that closely resembled the natural endochondral process resulting in bone ossicle formation. Assessment in a critical size long-bone defect in immunodeficient mice demonstrated successful bridging of the defect within 4 weeks, with active contribution of the implanted cells. In short, the presented serum-free process represents a biomimetic strategy, resulting in a cartilage tissue intermediate that, upon implantation, robustly leads to the healing of a large long-bone defect.
用于再生医学的基于细胞的策略的临床转化需要可预测的体内性能,而体外制备过程中使用血清会固有地限制疗效和可重复性。在此,我们提出一种受生物启发的方法,即对人骨膜来源的细胞进行无血清预处理,然后将它们组装成同时用骨形态发生蛋白2(BMP-2)引发的微聚集体。预处理产生了更具潜能的祖细胞群体,而聚集诱导了骨软骨生成分化,BMP-2刺激进一步增强了这种分化。异位植入显示出一系列与自然软骨内成骨过程极为相似的事件,导致骨小体形成。在免疫缺陷小鼠的临界尺寸长骨缺损模型中的评估表明,植入细胞在4周内成功桥接了缺损。简而言之,所提出的无血清方法代表了一种仿生策略,产生了一种软骨组织中间体,植入后能有力地促进大型长骨缺损的愈合。